Why Twist Bioscience Corporation (TWST) stock moved
Twist Bioscience Corporation (TWST) shares rose 4.9% to $124.41 as of August 18, 2026, a moderate gain from the prior close of $118.57. BestStocks flagged the session as a major change for TWST. The move is tied to price move up. Below, we break down what changed for TWST, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
TWST climbed 4.9% to $124.41
TWST rose 4.9% in its latest session, moving from $118.57 to $124.41.
What it means for Twist Bioscience Corporation investors
For Twist Bioscience Corporation investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Positive 4.9% session move. Weighing against that: TWST moved -2.95% from its $112.40 open to a $109.08 close on 2026-08-06; Twist Bioscience Corporation (TWST) moved −6.69% from $106.58 to $99.44 on 2026-08-04. Wall Street's consensus price target sits at $104.67, implying -15.9% downside from $124.41. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality low (55/100). With earnings roughly 87 days out, the next report is the most likely near-term test of the move.
TWST price reaction
TWST last traded at $124.41, up $5.84 (+4.93%) from the previous close of $118.57. The session traded on 0.6× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $85.47 and $125.29, and it currently sits about 98% of the way up that band.
Bullish and bearish analyst opinions on Twist Bioscience Corporation (TWST)
The consensus analyst price target on Twist Bioscience Corporation (TWST) is $104.67, 15.9% below the recent $124.41. Over the past 90 days analysts logged 0 upgrades, 7 maintains, and 1 downgrade. Here is how the bullish and bearish cases on TWST line up.
The bullish case
- Material positive event.
- Positive 4.9% session move.
- Twist Bioscience Corporation (TWST) moved +10.34% from $113.18 to $124.88 on 2026-08-10.
The bearish case
- The consensus analyst price target of $104.67 sits 15.9% below the recent $124.41, so the average target sees limited room to run.
- The most bearish analyst target is $89.00 (-28.5%).
- 1 analyst downgrade in the past 90 days, most recently Evercore ISI Group to In Line (2026-07-06).
- TWST moved -2.95% from its $112.40 open to a $109.08 close on 2026-08-06.
- Twist Bioscience Corporation (TWST) moved −6.69% from $106.58 to $99.44 on 2026-08-04.
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Aug 18, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for TWST
In-depth TWST event analyses
Frequently asked questions about TWST
Why did Twist Bioscience Corporation (TWST) stock move?
TWST rose 4.9% to $124.41. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did TWST stock rise?
TWST gained 4.93% ($5.84) versus the prior close of $118.57, last trading at $124.41 on 0.6× average volume.
When is Twist Bioscience Corporation's next earnings date?
TWST's next earnings report is estimated for 2026-11-13 — about 87 days away.
What is the analyst price target for TWST?
The consensus analyst price target for TWST is $104.67, about 15.9% below the current $124.41. Over the past 90 days, analysts recorded 0 upgrades, 7 maintains, and 1 downgrade.
How BestStocks tracks TWST
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for TWST, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of August 18, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.